86 results about "Semaglutide" patented technology

The application relates to application of semaglutide in preparation of a medicine for treating or delaying ovarian aging, and through a natural aging mouse model, a cell aging model and transcriptome analysis, it is first proved that semaglutide can significantly increase the number of follicles and reduce the level of aging markers, and from a molecular level, it is revealed that the mechanism of realizing multi-target point delay of ovarian aging is that semaglutide realizes multi-target point delay of ovarian aging through regulating an adipocyte cytokine signal pathway, inhibiting excessive cell division and regulating an NF-kappa B signal pathway. As a marketed drug, semaglutide has clear safety, a long half-life and high patient compliance, and has a significant clinical conversion prospect. The application breaks through the limitation that existing hormone replacement therapy and assisted reproductive technology can only treat symptoms or solve the problem of fertility, provides a first drug intervention strategy which can fundamentally delay the process of follicle depletion, and fills the blank in the field of ovarian aging treatment.

A preparation method for semaglutide. The method comprises: producing a semaglutide resin by means of a solid-phase synthesis, producing crude semaglutide by cleavage and deprotection, producing refined semaglutide by purification and freeze-drying, comprising the solid-phase synthesis of a semaglutide 1-6 peptide fragment resin, which is cleaved and purified to serve as a first peptide fragment; and synthesizing a lysine having a sidechain group at locus 20 of semaglutide to serve as a second peptide fragment. In the method, prepared is a semaglutide loci 1-6 fully protected peptide fragment, which serves as a key starting material applied in the solid-phase synthesis of semaglutide, thus reducing the generation of D-His, D-Glu, D-Thr, D-Phe racemic impurities and +Gly impurities, reducing the difficulty of coarse product purification, increasing the purity and yield of semaglutide, reducing synthesis costs, and favoring industrialized large-scale production.

The present disclosure provides methods for treating an inflammatory disease or disorder, wherein the inflammatory disease or disorder is a metabolic disease or disorder, comprising administration of a GLP-1 receptor agonist (e.g., semaglutide, exendin-4), and an IL-2 protein (e.g., aldesleukin) to a subject. Also presented herein are compositions for use with the methods disclosed herein and kits for administering a GLP-1 receptor agonist (e.g., semaglutide, exendin- 4), and an IL-2 protein (e.g., aldesleukin).

The invention discloses a preparation rich in polygonatum sibiricum polypeptide and application of the preparation in diabetes mellitus. The composition is prepared from rhizoma polygonati polypeptide, semeglutide, astaxanthin, an active agent and a ferroptosis mixture. Pharmacodynamic experiments show that in a diabetic mouse model, fasting blood glucose can be remarkably reduced, the serum insulin level can be increased, renal function indexes can be improved, and expression of NLRP3 inflammation pathway related proteins (NLRP3, Caspase-1 and IL-1beta) in pancreatic tissue can be remarkably inhibited. By integrating multiple mechanisms of blood glucose reduction, oxidation resistance, inflammation resistance, ferroptosis resistance and the like, multi-target collaborative intervention is realized, the pharmaceutical composition is remarkably superior to a single component in the aspects of blood glucose reduction, pancreas islet function protection and complication alleviation, and a new clinical strategy is provided for treatment of diabetes mellitus, especially type 1 diabetes mellitus.

Dry powder formulations of GLP-1 receptor agonists, such as semaglutide, dosage forms containing the same, and liquid feedstocks for preparing dosage forms, such as dry powers, that contain GLP-1 receptor agonists, are disclosed. Also disclosed are liquid formulations of GLP-1 receptor agonists, such as semaglutide.

The present invention relates to the general field of amino acids and peptides. In particular, the present invention relates to solid metal complex salts of amino acids or peptides, to processes for preparing such solid metal complex salts and to the use of such salts in the preparation of semeglutide, tiall and pharmaceutically acceptable salts thereof.

A computer implemented method for determining a dosage of semaglutide for administering to a patient for the treatment of obesity includes receiving patient data relating to a patient, wherein the patient data includes patient weight data; processing the patient data with a dosage calculator to determine the dosage of semaglutide for administering to the patient; and administering the dosage.

Disclosed herein are therapeutic uses of myostatin-selective inhibitors, such as myostatin-selective inhibitors, for treating metabolic disorders, such as obesity. Data presented herein support the notion that selectively targeting myostatin without inhibiting Activin A can achieve equivalent or enhanced efficacy when used in conjunction with a GLP-1 receptor agonist in improving body composition, as compared to broadly antagonizing the ActRII pathway in conjunction with a GLP-1 receptor agonist. Administration of a myostatin-selective inhibitor can prolong the effect of semaglutide on fat mass loss. Moreover, administration of a myostatin-selective inhibitor can elicit positive effects on bone in all parameters evaluated, indicating that diet- or inflammation-induced bone atrophy may be prevented by selective inhibition of the myostatin pathway.

The invention belongs to the technical field of biological medicine, and relates to a brain-targeted delivery system of semeglutide as well as a preparation method and application of the brain-targeted delivery system of semeglutide, the delivery system comprises yeast microcapsules and a semeglutide-cationic polymer; the delivery system takes a yeast microcapsule as a delivery carrier, and a semeglutide-cationic polymer is encapsulated in the yeast microcapsule. By simulating a natural way that microorganisms are recognized by macrophages through digestive tracts, active uptake is realized by utilizing specific binding of yeast microcapsules and Dectin-1 receptors on the surfaces of the macrophages, the semeglutide is accurately delivered to the brain by virtue of the cross-blood-brain-barrier migration ability of the macrophages, a central GLP-1 receptor pathway is activated to regulate metabolism, and meanwhile, the semeglutide can be used for preparing a medicine for treating liver cancer. According to the system, the oral bioavailability of the semeglutide can be improved, and non-specific distribution of the whole body is reduced.

The application belongs to the technical field of hydrogel preparation, and particularly relates to a hydrogel loaded with semaglutide and a preparation method and application thereof. The preparation method comprises the following steps: adding ferulic acid modified chitosan into deionized water to obtain a modified chitosan solution, adding oxidized dextran into deionized water, ultrasonic dissolving to obtain an oxidized dextran solution, adding semaglutide into the oxidized dextran solution to obtain an oxidized dextran mixed solution, and mixing the modified chitosan solution and the oxidized dextran mixed solution to obtain the hydrogel loaded with semaglutide. The hydrogel loaded with semaglutide has the advantages of short gelation time, good injection performance, non-toxicity and good biocompatibility. The hydrogel can significantly reduce myocardial interstitial fibrosis after myocardial infarction and improve the ejection capacity of the heart after myocardial infarction. The hydrogel can be used for preparing drugs for treating myocardial infarction.

Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes and / or obesity and / or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and / or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein.

The invention relates to the field of drug synthesis, and discloses a method for preparing semeglutide through fragment condensation, which comprises the following steps: taking 1-4 amino acids of a semeglutide amino acid sequence as a fragment I, 1-16 amino acids of the amino acid sequence as a fragment II, 17-29 amino acids of the amino acid sequence as a fragment III, and 30-31 amino acids of the amino acid sequence as a fragment IV; preparing the first fragment, the second fragment, the third fragment and the fourth fragment into a semeglutide product by adopting a solid-liquid combination method; the fragment I of the method can effectively inhibit racemization impurities of His; the C-terminal amino acids of the second fragment, the third fragment and the fourth fragment in the method are all Gly, and racemization impurities cannot be generated when the three fragments are condensed. In addition, the fragment synthesized by the fragment II, the fragment III and the fragment IV is high in purity and good in solubility, the condensation reaction efficiency of the polypeptide fragment is high, the fragment utilization rate is high, the cost is low, the unutilized fragment can be extracted and separated, and the post-treatment is simple.

The present invention relates to a depot composition comprising calcium chloride in the interior of microspheres. The depot composition according to the present invention can control the excessive release of the effective ingredient contained in the interior of the microspheres at the initial stage of the depot injection by using calcium chloride as a cationic salt. In addition, the composition has excellent suspendability and a very small amount of residual solvent, and thus the effect of the effective ingredient can be uniformly and continuously obtained even if the user administers it in the form of an injection. In addition, an improved medical therapy of semaglutide can be provided by adjusting the dose of semaglutide or tirzepatide through the depot dosage form.

The invention discloses a method for preparing semeglutide by using a natural chemical ligation method, which comprises the following steps: (1) synthesizing semeglutide in two segments, namely an N-terminal segment with carboxyl-terminal hydrazide and a C-terminal segment with amino-terminal cysteine; (2) connecting the two fragments through a natural chemical connection method under a buffer salt condition; and (3) performing desulfurization treatment to convert Cys into target amino acid, and performing purification and freeze-drying after complete treatment. According to the method, the semeglutide is divided into the C-terminal polypeptide fragment and the N-terminal polypeptide fragment, the C-terminal polypeptide fragment and the N-terminal polypeptide fragment are connected through natural chemical connection reaction after being prepared respectively, then desulfurization treatment is conducted, the high-purity and high-yield semeglutide is finally obtained, the problem of difficult sequences is solved, the synthesis efficiency and purity of the semeglutide are remarkably improved, and the method is suitable for industrial production. The method is suitable for large-scale production.

The invention relates to the technical field of medicines, in particular to a process quality control method of semeglutide, which is characterized in that a compound 1 has serious solution instability and can be quickly degraded along with time, and in a subsequent synthesis process, it must be ensured that an intermediate which is prepared freshly or is confirmed to be qualified in purity is used, and high performance liquid chromatography process monitoring is introduced. The invention provides a high performance liquid chromatography real-time monitoring method matched with a compound 1 to accurately control the reaction process so as to effectively inhibit an impurity chain reaction caused by degradation of raw materials, and for the characteristics of instability and continuous decomposition of the compound 1 in a solution, the invention provides a high performance liquid chromatography real-time monitoring method matched with the compound 1. The raw material conversion rate and the generation conditions of key over-modified impurities 1 and 2 can be synchronously monitored in the reaction process, and the raw material peak area smaller than or equal to 2.0% and the specific impurity peak area smaller than or equal to 5.0% (or 2.0%) serve as scientific and accurate reaction termination criteria. According to the active process control strategy, accumulation of impurities is inhibited from the source, and the problems of inaccurate feeding and batch difference caused by degradation of intermediates are solved.

The invention provides a method for purifying semeglutide, and relates to the technical field of separation and purification. According to the method for purifying the semeglutide, provided by the invention, a chromatographic column filler adopted in semi-preparative chromatographic separation is an HZ-71 chromatographic series filler, and the filler is made of polyacrylic acid microspheres which have uniform particle sizes and pore structures, are monodisperse microspheres with pore structures and have good selectivity on the semeglutide. According to the purification method provided by the invention, the pure semeglutide product with the purity of more than 95% can be obtained only through one-step semi-preparative chromatographic separation, the obtained pure semeglutide product is high and stable in purity, multi-step chromatographic purification is not needed, the operation is simple, the production cost is reduced, the filler is relatively easy to regenerate, the separation efficiency is slowly reduced, and the method is suitable for industrial production. The chromatographic column can be continuously loaded for multiple times after being balanced for one time, a pure product of the semeglutide can be continuously prepared and produced, and the method is suitable for industrial production.

The present invention relates to a pharmaceutical composition useful for prevention or treatment of diabetes, beta-cell function preservation, high blood pressure, hyperlipidemia, obesity, non-alcoholic steatohepatitis or neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, as it comprises a sustained-release microsphere comprising semaglutide, a pharmaceutically acceptable salt, hydrate or solvate thereof, and thereby, it can effectively inhibit fatal side-effects by preventing initial burst of a drug and comprise a high content of drug compared to a particle size, and therefore, it can minimize the patient's pain and inflammatory reaction that may occur during administration.

The present application relates to a kind of soluble microneedle patch of semaglutide peptide and its preparation method and purposes.The soluble microneedle patch of semaglutide peptide includes drug-loaded needle tip layer and back plate layer;Wherein, the drug-loaded needle tip layer includes semaglutide and needle tip layer matrix material;With the total weight of the drug-loaded needle tip layer 100% as 100%, the weight percentage of semaglutide is 85%~99%, and the weight percentage of the needle tip layer matrix material is 1%~15%.The needle type of the soluble microneedle patch of semaglutide is excellent, and the mechanical strength and skin puncture performance are superior, and the safety is high, and drug release and penetration rate are fast, and drug penetration rate is high, with excellent drug utilization and bioavailability;Its preparation method is simple, and controllability is good, and it is suitable for large-scale production.In addition, the soluble microneedle patch of semaglutide is convenient and fast, and patient compliance is high, with wide clinical application prospect.

The present disclosure provides methods for treating an inflammatory disease or disorder, wherein the inflammatory disease or disorder is an autoimmune disease or disorder, comprising administration of a GLP-1 receptor agonist (e.g., semaglutide, exendin-4), and an IL-2 protein (e.g., aldesleukin) to a subject. Also presented herein are compositions for use with the methods disclosed herein and kits for administering a GLP-1 receptor agonist (e.g., semaglutide, exendin- 4), and an IL-2 protein (e.g., aldesleukin).

The objective invention provides a parenteral composition of semaglutide or a pharmaceutically acceptable salt thereof for subcutaneous administration, having a strength and composition such that it can be administered multiple times from single article of manufacture, for use in treating type 2 diabetes mellitus and for weight loss, thereby providing benefit to the patient.

Disclosed herein is a further medical use of semaglutide, namely semaglutide in the treatment of intermittent claudication in a human subject with diabetes and peripheral arterial disease. Semaglutide is shown to have a positive impact on symptoms of intermittent claudication and therefore the functional limb capacity and quality of life of patients with type 2 diabetes and peripheral arterial disease.

Sublingual Semaglutide compositions may comprise both Semaglutide or a salt thereof and a gastric peptide or salt thereof, in combination. The use of a gastric peptide mitigates gastrointestinal side effects of Semaglutide. A weight loss regimen comprises administration of sublingual Semaglutide compositions in the physical form of sublingual tablets. In preferred embodiments, each sublingual Semaglutide tablet provides about 500 mcg Semaglutide or 750 mcg Semaglutide in combination with 300 mcg of gastric peptide, with the gastric peptide preferably comprising Body Protection Compound-157 (BPC-157). Sublingual administration of Semaglutide finds use in suppressing appetite, losing weight, and maintaining a desired personal appearance.

The present disclosure provides formulations, methods and implantable devices that improve patient compliance by releasing a desired therapeutic agent such as semaglutide for a long time period, such as 1 year or more. The semaglutide concentration (w / w) is more than 1%, such as about 1.1% w / w to about 35% w / w.

The invention relates to a semi-synthesis method of semeglutide, and belongs to the field of chemical synthesis. The semi-synthesis method mainly comprises the following steps: (1) activating a side chain; (2) connecting an activated side chain with an Arg34GLP-1 (9-37) 29 peptide; (3) activating the dipeptide; (4) connection of the activated dipeptide and the side chain 29 peptide conjugate; (5) removing a protecting group to obtain a final product, namely a crude product of the semeglutide; meanwhile, pretreatment of materials and post-treatment of products are optimized in the synthesis process. On one hand, a side chain and dipeptide activation method which is short in time consumption and high in conversion rate is provided, on the other hand, an intermediate pretreatment and post-treatment method which is convenient, rapid, beneficial to reaction and beneficial to cost reduction and efficiency improvement is provided, the characters of substrates / products in all the steps are improved, cost reduction, production specification expansion and efficiency improvement in industrial production are facilitated, and the method is suitable for industrial production. And the method has very important significance on industrial production of a semeglutide bulk drug.

This disclosure provides methods of treatment, prevention, and / or amelioration of obesity, obstructive sleep apnea / hypopnea syndrome (OSAHS), and related comorbidities using antibodies and antigen binding fragments thereof that binds to cannabinoid receptor 1 (CB1) receptor alone or in combination with GLP-1 agonists, e.g., semaglutide or incretins.

The present disclosure provides a GLP-1 receptor agonist semaglutide for use in medical therapy including weight management.

Disclosed is a sustained-release formulation of semaglutide. The sustained-release formulation of semaglutide comprises semaglutide or a pharmaceutically acceptable salt thereof, triacylglycerol, phosphatidylcholine, absolute ethanol, a solubilizer, and a pH regulator.

The present invention relates to a composition for manufacturing a microarray comprising semaglutide as an active ingredient, a microarray manufactured using the composition, a method for manufacturing the microarray, and an assembly comprising the microarray. The microarray of the present invention has excellent stability allowing storage and transportation at room temperature and exhibits pharmacokinetic characteristics similar to those of subcutaneous injection.

Disclosed herein is a further medical use of semaglutide, namely semaglutide in the treatment of intermittent claudication in a human subject with diabetes and peripheral arterial disease. Semaglutide is shown to have a positive impact on symptoms of intermittent claudication and therefore the functional limb capacity and quality of life of patients with type 2 diabetes and peripheral arterial disease.

An oral thin film (OTF) containing semaglutide, methods of manufacturing the same, and methods or orally administering the same.